- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01251874
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Studienübersicht
Status
Bedingungen
- Mutation des BRCA1-Gens
- Mutation des BRCA2-Gens
- Rezidivierendes Mammakarzinom
- Östrogenrezeptor negativ
- Östrogenrezeptor positiv
- HER2/Neu-Negativ
- Progesteronrezeptor negativ
- Progesteronrezeptor positiv
- Triple-negatives Mammakarzinom
- Brustkrebs im Stadium IV AJCC v6 und v7
- Brustkrebs im Stadium IIIB AJCC v7
- Brustkrebs im Stadium IIIC AJCC v7
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose of veliparib along with carboplatin on a 14-day and 21-day schedule in patients with Her2 negative metastatic breast cancer that are estrogen receptor (ER)/progesterone receptor(PR) negative or ER and/or PR positive with defects in Fanconi Anemia (FA) pathway repair genes.
II. To determine the safety and tolerability of combining veliparib on a 14-day and 21-day schedule with carboplatin in this patient population.
III. To determine the preliminary efficacy of this combination in this patient population.
SECONDARY OBJECTIVES:
I. To determine the pharmacodynamic endpoints of poly(ADP-ribose) polymerase (PARP) inhibition in the tumor by using, A) 3'-[F-18]fluoro-3'-deoxythymidine positron emission tomography (FLT-PET) of the target lesions, B) circulating tumor cells to detect the induction of the histone variant gamma H2AX, and C) peripheral blood mononuclear cells to assess poly ADP-Ribose (PAR) levels.
II. To determine biomarkers in the primary tumor that may predict antitumor responses to PARP inhibition such as breast cancer 1/2, early onset (BRCA)1/2 protein, Fanconi anemia, complementation group D2 (FANCD2) nuclear foci formation and expression of micro-ribonucleic acid (RNA) 155 (miR 155).
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive carboplatin intravenously (IV) over 1 hour on day 1 and veliparib orally (PO) twice daily (BID) on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 12 weeks.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
New York
-
Bronx, New York, Vereinigte Staaten, 10461
- Montefiore Medical Center-Einstein Campus
-
Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center - Moses Campus
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Patients must have histologically or cytologically proven metastatic or locally advanced inoperable breast cancer that fulfills one of the following two criteria:
- Triple-negative breast cancer
- ER and/or PR positive, HER2 negative if their tumors have been shown to be deficient for the FA pathway, based on FA triple stain immunofluorescence (FATSI) screening
HER negative with a known germline BRCA1/2 mutation
- Patients with ER- and/or PR-positive breast cancer will be consented to have their existing, or to be obtained, paraffin-embedded tumor tissue screened for FA deficiency
- No more than 3 prior chemotherapy regimens for metastatic disease will be allowed; any number of prior hormone therapies will be allowed; however, at least 4 weeks should have elapsed since prior chemotherapy (6 weeks for mitomycin C and nitrosoureas and 2 weeks for hormone therapy) or radiation therapy (2 weeks for limited field palliative radiation to the bone)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Patients with treated brain metastases and life expectancy of greater than 3 months
- Patients with known Gilbert syndrome with abnormal unconjugated bilirubin will be eligible
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic acid transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- No prior therapy with veliparib for metastatic disease will be allowed
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
- Patients must be able to swallow pills
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib
- Known human immunodeficiency virus (HIV)-infected patients on protease inhibitors are ineligible; HIV-infected patients with adequate cluster of differentiation (CD)4 counts (> 500) and not on protease inhibitors are eligible
- Patients with active seizure or a history of seizures are not eligible
- Patients with uncontrolled central nervous system (CNS) metastasis are not eligible; patients with CNS metastases must be stable after therapy for > 3 months and off steroid treatment prior to study enrollment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Treatment (veliparib, F 18 fluorothymidine, carboplatin)
Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
|
Korrelative Studien
Gegeben IV
Andere Namen:
Korrelative Studien
PO gegeben
Andere Namen:
Korrelative Studien
Andere Namen:
Korrelationsstudien
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Incidence of adverse events to measure the safety and tolerability of this treatment combination
Zeitfenster: Up to 12 weeks post-treatment
|
Number and severity of toxicity incidents will be tabulated.
Non-hematologic toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 standard toxicity grading.
Hematologic toxicity measures of thrombocytopenia, neutropenia and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir and percent change from baseline values) as well as categorization via CTCAE standard toxicity grading.
Frequency distributions and other descriptive measures will form the basis of the analysis of these variables.
|
Up to 12 weeks post-treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Clinical response (complete and partial response as well as stable and progressive disease)
Zeitfenster: Up to 12 weeks post-treatment
|
Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease.
Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors guideline (version 1.1).
|
Up to 12 weeks post-treatment
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
PARP-1 activity
Zeitfenster: Up to 5 years
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 5 years
|
Thymidine kinase uptake on 3'-[F-18]fluoro-3'-deoxythymidine positron emission tomography (FLT-PET) scans
Zeitfenster: Up to 18 weeks (after course 3)
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 18 weeks (after course 3)
|
Circulating tumor cell markers
Zeitfenster: Up to 5 years
|
Analysis will be descriptive and exploratory in nature.
Potential relationships and differences will be explored using graphical analyses and quantitative summaries of this marker.
|
Up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Bhuvaneswari Ramaswamy, Ohio State University Comprehensive Cancer Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Hautkrankheiten
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Neubildungen, Drüsen und Epithelien
- Brusterkrankungen
- Neoplasien der Brust
- Karzinom
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Poly(ADP-Ribose)-Polymerase-Inhibitoren
- Carboplatin
- Veliparab
- Alovudin
Andere Studien-ID-Nummern
- NCI-2011-02552 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- P30CA016058 (US NIH Stipendium/Vertrag)
- UM1CA186712 (US NIH Stipendium/Vertrag)
- U01CA076576 (US NIH Stipendium/Vertrag)
- 8609 (Andere Kennung: CTEP)
- CDR0000688990
- OSU 10080
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Mutation des BRCA1-Gens
-
National Cancer Institute (NCI)AbgeschlossenBRCA1-Gen | BRCA2-GenVereinigte Staaten
-
Weill Medical College of Cornell UniversityBasser Research Center for BRCARekrutierung
-
University of PennsylvaniaRekrutierungBRCA1-Mutation | BRCA2-MutationVereinigte Staaten
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Unbekannt
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; University of California, Los Angeles; Dana-Farber... und andere MitarbeiterAktiv, nicht rekrutierend
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutierungKrebs-Gen-MutationItalien
-
nVision MedicalAbgeschlossenBRCA1-Mutation | BRCA2-Mutation | Malignitätsverdächtige AtypieVereinigte Staaten
-
European Institute of OncologyAbgeschlossenBRCA1-Mutation | BRCA2-Mutation | Psychosoziale FaktorenItalien
-
Rabin Medical CenterUnbekanntMutation des BRCA1-Gens | Mutation des BRCA2-GensIsrael
-
University of PennsylvaniaInovio PharmaceuticalsRekrutierung
Klinische Studien zur Labor-Biomarker-Analyse
-
Vanderbilt University Medical Center4DMedicalAbgeschlossen
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Noch keine RekrutierungHIV-Infektionen | Hepatitis B
-
Duke UniversityZurückgezogenAntikoagulations- und Thrombose-Point-of-Care-Test (AT-POCT)Vereinigte Staaten
-
Columbia UniversityAbgeschlossen
-
McGill University Health Centre/Research Institute...Northwestern UniversityRekrutierungApnoe der FrühgeburtlichkeitKanada
-
Emory UniversityDermatology FoundationBeendetKutaner Lupus erythematodesVereinigte Staaten